Pour une meilleure utilisation, nous vous conseillons d’activer Javascript dans votre navigateur.

CD40 Ligand anticorps

CD40LG Reactivité: Humain, Souris WB, FACS, IHC, IF (cc) Hôte: Lapin Monoclonal 4C2 unconjugated

N° du produit ABIN6942438

Fiche de données

Antigène Voir toutes CD40 Ligand (CD40LG) Anticorps

CD40 Ligand (CD40LG)
Reactivité
147

79

35

9

9

7

6

3

3

3

2

2

2

2

2

1

1

1
Humain, Souris
Hôte
85

73

24

17

11

1
Lapin
Anticorps secondaires appropriés
Clonalité
124

81

4
Monoclonal
Conjugué
105

22

21

14

11

3

3

2

2

2

2

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1
Cet anticorp CD40 Ligand est non-conjugé
Application
119

101

56

48

38

31

21

17

14

13

13

13

7

7

5

4

4

3

2

2

2

2

1

1

1

1

1

1
Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (Cultured Cells) (IF (cc))

Réactivité croisée

Humain, Souris

Purification

Purified by Protein A.

Immunogène

N terminus human CD40L

Clone

4C2

Isotype

IgG

Top Product

Discover our top product CD40LG Anticorps primaire
anti-CD40 Ligand (CD40LG) (AA 1-261) antibody
CD40LG Reactivité: Humain WB, IHC, IP, ICC Hôte: Lapin Polyclonal unconjugated

anti-CD40 Ligand (CD40LG) (AA 108-261) antibody
CD40LG Reactivité: Humain FACS, IHC, ELISA, IF, Coat, StM Hôte: Souris Monoclonal CD40LG-2763 unconjugated

anti-CD40 Ligand (CD40LG) (AA 108-261) antibody
CD40LG Reactivité: Humain FACS, IHC, ELISA, IF, Coat, StM Hôte: Souris Monoclonal CD40LG-2761 unconjugated

anti-CD40 Ligand (CD40LG) antibody (FITC)
CD40LG Reactivité: Souris FACS Hôte: Hamster arménien Monoclonal MR-1 FITC

anti-CD40 Ligand (CD40LG) (AA 33-62), (N-Term) antibody
CD40LG Reactivité: Humain WB, FACS, IF, IHC (p) Hôte: Lapin Polyclonal RB19150 unconjugated

anti-CD40 Ligand (CD40LG) (AA 79-129) antibody
CD40LG Reactivité: Humain WB, IHC, IF Hôte: Lapin Polyclonal unconjugated

anti-CD40 Ligand (CD40LG) (AA 33-62) antibody
CD40LG Reactivité: Humain WB, FACS, IHC, ELISA, IF Hôte: Lapin Polyclonal unconjugated

anti-CD40 Ligand (CD40LG) (AA 111-261) antibody
CD40LG Reactivité: Porc WB, IHC, IP, ICC Hôte: Lapin Polyclonal unconjugated

anti-CD40 Ligand (CD40LG) antibody (PE)
CD40LG Reactivité: Humain, Non-Human Primate FACS Hôte: Souris Monoclonal 24-31 PE

anti-CD40 Ligand (CD40LG) antibody
CD40LG Reactivité: Humain, Souris, Rat WB, IF Hôte: Lapin Polyclonal unconjugated

Indications d'application

WB 1:300-5000
FCM 1:20-100
IF(ICC) 1:50-200
IHC()

Restrictions

For Research Use only
Format

Liquid

Concentration

1 μg/μL

Buffer

Aqueous buffered solution containing 1xTBS ( pH 7.4), 1 % BSA, 40 %Glycerol and 0.05 % Sodium Azide.

Agent conservateur

ProClin

Précaution d'utilisation

This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock

-20 °C

Stockage commentaire

Store at -20°C for 12 months.

Date de péremption

12 months
Antigène

CD40 Ligand (CD40LG)

Autre désignation

CD40L (CD40LG Produits)

Synonymes

anticorps CD154, anticorps cd40l, anticorps CD40L, anticorps HIGM1, anticorps IGM, anticorps IMD3, anticorps T-BAM, anticorps TNFSF5, anticorps TRAP, anticorps gp39, anticorps hCD40L, anticorps CD40-L, anticorps Cd40l, anticorps Ly-62, anticorps Ly62, anticorps Tnfsf5, anticorps CD40 ligand, anticorps TNF superfamily member 5, anticorps CD40LG, anticorps cd40l, anticorps Cd40lg

Sujet

Synonyms: CD40 ligand, T-cell antigen Gp39, TNF-related activation protein, Tumor necrosis factor ligand superfamily member 5, CD154, CD40 ligand, membrane form, CD40 ligand, soluble form, CD40-L, TRAP, CD40LG
Background: Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching. Release of soluble CD4L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.

ID gène

959

UniProt

P29965

Pathways

Signalisation NF-kappaB, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints